Medicure Reports Financial Results For Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 28, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused...
Clinical Trial
Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meetingSAN DIEGO, July 28, 2023...
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical...
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,...
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development...
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has completed the submission...
Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading...
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA...
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study...
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second IndicationCompany Selects Refractory Advanced Genitourinary Malignancies including Renal...
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised Paris, July 28, 2023 Q2 2023 sales...
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
Global Citeline Awards Recognize TrialWire™ Rapid Patient Recruitment Platform as “Best Patient-facing Technology Initiative 2023”
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- TrialWire™ Rapid Patient Recruitment Platform, the pay per enrollment recruitment service powered by...
Genmab Updates 2023 Financial Guidance
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its preliminary first half 2023 financial...
Small Pharma Reports Fiscal First Quarter 2024 Highlights
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an...
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in subjects with Stargardt Disease (STGD1)...
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current...
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of...